Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Receivables (2023 - 2025)

Historic Receivables for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $79000.0.

  • Artiva Biotherapeutics' Receivables fell 8873.04% to $79000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $79000.0, marking a year-over-year decrease of 8873.04%. This contributed to the annual value of $146000.0 for FY2024, which is 9169.51% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Receivables stood at $79000.0 for Q3 2025, which was down 8873.04% from $30000.0 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Receivables registered a high of $1.8 million during Q4 2023, and its lowest value of $30000.0 during Q2 2025.
  • For the 3-year period, Artiva Biotherapeutics' Receivables averaged around $629857.1, with its median value being $234000.0 (2025).
  • The largest annual percentage gain for Artiva Biotherapeutics' Receivables in the last 5 years was 8873.04% (2025), contrasted with its biggest fall of 9794.66% (2025).
  • Artiva Biotherapeutics' Receivables (Quarter) stood at $1.8 million in 2023, then plummeted by 91.7% to $146000.0 in 2024, then tumbled by 45.89% to $79000.0 in 2025.
  • Its Receivables was $79000.0 in Q3 2025, compared to $30000.0 in Q2 2025 and $234000.0 in Q1 2025.